FindTrial
Sign In

To compare effectiveness of two drugs dexmedetomidine and lignocaine ,given with nebuliser in decreasing haemodynamic response to laryngoscopy and intubation done during general anaesthesia.

To compare efficacy of nebulised dexmedetomidine vs nebulised lignocaine for blunting haemodynamic response to laryngoscopy and intubation: A Randomised Controlled Trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/02/040460
Enrollment
90
Registered
2022-02-21
Start date
Unknown
Completion date
Unknown
Last updated
2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Nebulisation with dexmedetomidine: Patient will be nebulised with dexmedetomidine 1mcg/kg Control Intervention1: Nebulisation with lignocaine: Patient will be nebulised with lignocaine

Sponsors

Dr Taranpreet Kaur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ASA grade I and II MPS grade I and II Patients undergoing various elective surgeries under general anaesthesia.

Exclusion criteria

Exclusion criteria: 1. BMI >30 kg /m2. 2. Allergies to lignocaine/dexmedetomidine. 3. Patients with heart block. 4. Patients with bradycardia (HR 5. Hypotension (BP 6. Patient with any cardiac disease. 7. Patient with a difficult airway. 8. Patient refusing consent. 9. Patient on beta blockers.

Design outcomes

Primary

MeasureTime frame
MAP , SBP, DBP,HR,SpO2Timepoint: 0min 5min 10min 15min Before induction Post intubation: 1min 3min 5min 7min 10min—

Secondary

MeasureTime frame
Dose of proposal used.Timepoint: During induction;Sore throat incidence and grading. Timepoint: After 24 hours of surgery—

Countries

India

Contacts

Public ContactTaranpreet Kaur

Indira Gandhi Medical College,Shimla

drrameshkumar66@gmail.com9418077428

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026